TABLE 3.
Carbapenem susceptibility testing data for carbapenem-resistant Enterobacterales and carbapenem-resistant Pseudomonas aeruginosa isolates, characterized by carbapenemase genes detected according to the Antibiotic Resistance Laboratory Network, 2018 to 2019
| Organism and drug | No. (%) of isolates with carbapenemase genea |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
bla
KPC
|
bla
NDM
|
bla
VIM
|
bla
IMP
|
bla
OXA-48-like
|
|||||||||||
| Tested | R | I | Tested | R | I | Tested | R | I | Tested | R | I | Tested | R | I | |
| Carbapenem-resistant Enterobacteralesb | |||||||||||||||
| Ertapenem | 7,279 | 6,501 (89) | 615 (8) | 796 | 789 (99) | 6 (1) | 69 | 55 (80) | 12 (17) | 106 | 88 (83) | 11 (10) | 279 | 224 (80) | 47 (17) |
| Meropenem | 7,160 | 5,868 (82) | 605 (8) | 803 | 787 (98) | 9 (1) | 73 | 63 (86) | 2 (3) | 95 | 67 (71) | 9 (9) | 273 | 124 (45) | 36 (13) |
| Imipenem | 6,026 | 4,806 (80) | 859 (14) | 714 | 694 (97) | 15 (2) | 71 | 65 (92) | 2 (3) | 91 | 42 (46) | 35 (38) | 236 | 95 (40) | 53 (22) |
| Doripenem | 4,140 | 2,097 (51) | 1,091 (26) | 345 | 321 (93) | 17 (5) | 19 | 11 (58) | 2 (11) | 49 | 28 (57) | 11 (22) | 200 | 54 (27) | 30 (15) |
| Carbapenem-resistant P. aeruginosac | |||||||||||||||
| Meropenem | 121 | 114 (94) | 1 (1) | 29 | 28 (97) | 0 (0) | 231 | 223 (97) | 5 (2) | 39 | 39 (100) | 0 | ND | ND | ND |
| Imipenem | 111 | 104 (94) | 1 (1) | 28 | 28 (100) | 0 (0) | 228 | 225 (99) | 2 (1) | 37 | 36 (97) | 0 | ND | ND | ND |
| Doripenemd | 55 | 48 (87) | 21 | 21 (100) | 131 | 128 (98) | 33 | 33 (100) | ND | ND | ND | ||||
Abbreviations: ND, not detected; R, resistant; I, intermediate. Genes are arranged by carbapenemase class; class B metallo-β-lactamase genes include blaNDM, blaVIM, and blaIMP. Excluded are isolates with >1 carbapenemase gene detected. Not all isolates were tested for all drugs listed.
Carbapenem-resistant Enterobacterales isolates tested at public health laboratories were defined as any clinical isolate of Enterobacterales resistant to ertapenem, imipenem, meropenem, or doripenem (MICs of ≥4 μg/ml for imipenem, meropenem, and doripenem or ≥2 μg/ml for ertapenem) at the submitting clinical laboratory. Interpretations were based on Clinical Laboratory and Standards Institute breakpoints.
Carbapenem-resistant isolates of Pseudomonas aeruginosa tested at public health laboratories were defined as any clinical isolate of P. aeruginosa resistant to imipenem, meropenem, or doripenem (MICs of ≥8 μg/ml) at the submitting clinical laboratory. Interpretations were based on Clinical Laboratory and Standards Institute breakpoints.
Excludes data from laboratories using commercial broth microdilution panels where intermediate and resistant doripenem interpretations could not be distinguished.